2023 kicks off with strong support for longevity research and a huge step for decentralized science (DeSci)
January 30, 2023 (Berlin, Germany and Ottawa, Canada) — VitaDAO is excited to announce that it has closed a $4.1m fundraising round from strategic members including Pfizer Ventures, Shine Capital, L1 Digital; decentralised science and web3 organisations Beaker DAO and Spaceship DAO; and longevity enthusiasts including Balaji Srinivasan (former CTO of Coinbase and General Partner at a16z) and Joe Betts-LaCroix (Retro Biosciences) and many others.
The proceeds from the fundraise will be used to fund further longevity research projects and precede the spinout of VitaDAO’s first biotech startups, scheduled in the first quarter of 2023, as well as further investment in commercialization and licensing of its IP-NFT assets through its partnership with Molecule DAO.
“2022 was a highly successful year for VitaDAO, and the quality of research we have seen has been impressive,” says Laurence Ion, Steward of the Dealflow Working Group. “We’ve also seen some of our projects move rapidly to the next stage in development — such as entering into clinical trials with Mantis Photonics and new data from the Morten Scheibye-Knudsen Lab at the University of Copenhagen and the Victor Korolchuk Lab at the University of Newcastle. This has further proven that a highly aligned community can contribute to advancing the science and clinical innovation in longevity research.”
The fundraising is an important milestone for VitaDAO and will allow the organisation to accelerate its mission of extending human life and healthspan. With these new funds, VitaDAO will be able to fund cutting-edge longevity research, commercialise new technologies that target human aging, and build out its global community of experts and enthusiasts.
Pfizer is the first pharma to vote on DAO proposals (within VitaDAO), and also participates in VitaDAO in many other ways, including dealflow, scientific evaluation, incubation, and commercialization.
VitaDAO wishes to thank its contributors for their support.
VitaDAO is a global community for the acceleration of research and development (R&D) in longevity science and the extension of human health- and life-span. VitaDAO achieves this through funding and incubating research and researchers using the tools of decentralised science (“DeSci”) to reduce the time for therapeutic development and, ultimately, bring aging under medical control.
VitaDAO, with a community of over 9000 enthusiasts, researchers, and contributors, in 2022 deployed over $3.5M USD in 15+ projects researching the diseases of ageing, with a focus on cellular biology and the repair of damage associated with the hallmarks of ageing.
All researchers are welcome to apply for funding, including professors, post-docs, research scientists, and even students.
VitaDAO is defined as an active and diverse community of contributors. Everyone can contribute to VitaDAO. We’re looking for researchers to identify and assess longevity projects and non-researchers to help with tech, legal, awareness, and operations. Join us.
For media, please contact:
Community and Awareness Steward
Official Twitter: @vita_dao
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times journalist was involved in the writing and production of this article.